[go: up one dir, main page]

EP2831275A1 - Séquences marqueurs de la polyarthrite rhumatoïde - Google Patents

Séquences marqueurs de la polyarthrite rhumatoïde

Info

Publication number
EP2831275A1
EP2831275A1 EP13718795.1A EP13718795A EP2831275A1 EP 2831275 A1 EP2831275 A1 EP 2831275A1 EP 13718795 A EP13718795 A EP 13718795A EP 2831275 A1 EP2831275 A1 EP 2831275A1
Authority
EP
European Patent Office
Prior art keywords
seq
marker
sequences
sequence
rheumatoid arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13718795.1A
Other languages
German (de)
English (en)
Inventor
Angelika LÜKING
Peter Schulz-Knappe
Heike GÖHLER
Martin GAMER
Carmen THEEK
Daniel Chamrad
Anna TELAAR
Matthias VON DARL
Matthias Schneider
Jessica SCHWERMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagen GmbH
Original Assignee
Protagen GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP12161628.8A external-priority patent/EP2644704A1/fr
Application filed by Protagen GmbH filed Critical Protagen GmbH
Priority to EP13718795.1A priority Critical patent/EP2831275A1/fr
Publication of EP2831275A1 publication Critical patent/EP2831275A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Definitions

  • the present invention relates to a novel method for the identification of marker sequences for rheumatoid arthritis, the novel marker sequences found by means of the method and their diagnostic use. Furthermore, the present invention relates to a novel method for the identification of marker sequences for rheumatoid arthritis, the novel marker sequences found by means of the method and their diagnostic use. Furthermore, the present invention relates to a novel method for the identification of marker sequences for rheumatoid arthritis, the novel marker sequences found by means of the method and their diagnostic use. Furthermore, the
  • Marker sequences for rheumatoid arthritis in particular a protein biochip or beads and their use.
  • Protein biochips are gaining an increasing industrial
  • Protein biochips require the necessary proteins to be available. In particular,
  • the cDNA of a particular tissue in a bacterial or a eukaryotic expression vector, such as yeast, is cloned.
  • the vectors used for the expression are generally characterized by the fact that they carry inducible promoters, with which the timing of protein expression can be controlled.
  • expression vectors have sequences for so-called
  • Affinity epitopes or proteins on the one hand for the specific detection of the recombinant fusion proteins by means of a directed against the affinity epitope
  • Antibody on the other hand becomes the specific one
  • Expression libraries could also be expressed and purified at high throughput (Braun P., Hu, Y., Shen,
  • antibody-presenting arrangements are also described (Lal et al (2002) Antibody arrays: An embryonic but growing technology, DDT, 7, 143-149, Kusnezow et al., (2003) Antibody microarrays: An evaluation of production parameters, Proteomics, 3, 254-264).
  • RA Arthritis
  • the arrays are incubated with the serum samples and conjugated to anti-human IgG via Alexa Fluor 647
  • EP 1 731 608 A1 discloses a method to identify "RA susceptible genes" by gene mapping using microsatellite markers and PCR technique The genes were TNXB, NOTCH4 (chromosomes 6), RAB6A, MPRL48, FLJ11848, UCP2 and UCP3 (chromosome 11) in human genomic DNA
  • EP 1 731 608 A1 claims a marker gene for an RA assay consisting of a partial DNA sequence of one of the marker genes found and comprising at least one SNP in the human genomic DNA of RA comprising recovering partial DNA sequences corresponding to one of the marker genes from a subject to be examined, determining the nucleotide sequence of the partial DNA sequence and comparing the nucleotide sequence with the corresponding nucleotide sequence derived from a
  • test kit for RA comprising one of the marker genes or one of them
  • derived primer a polypeptide encoded by one of the marker genes and a screening method.
  • WO 2009/138408 A2 claims a diagnostic method in which an autoantigen marker comprising the catalytic domain of BRAF or an antibody fragment thereof, for
  • Detection of RA is used and optionally also anti-PAD4 antibodies are detected in the biological sample of the subject to be examined.
  • WO 2009/138408 A2 discloses a detection kit for the detection of anti-BRAF
  • WO 2007/039280 AI claims a method for
  • WO 2007/039280 A1 further claims the use of a panel comprising anti-CCP and ANA for the diagnosis of RA and a test kit.
  • WO 2005/032328 A2 claims a method for the detection of RA in a sample of a patient wherein the amount of one or more markers selected from Table 1 (679 markers are mentioned there) or Table 2 (some of the markers from Table 1) compared to a check with normal
  • 2005/032328 A2 also discloses to distinguish with certain markers between progressive and non-progressive RA.
  • WO 2005/032328 A2 the markers for RA in the serum of patients are identified by means of MS.
  • WO 2005/061692 AI claims a protein microarray
  • WO 2005/061692 A1 also mentions a method for screening RA using said proteins, a drug containing one of the proteins, and a kit for screening RA. In order to identify the above-mentioned proteins, WO 2005/061692 A1 proposes to compare serum of patients with that of healthy control persons (page 6, paragraph 3).
  • Antibodies for the diagnosis of RA in CCP-negative patients and use for monitoring during therapy with infliximab There are groups of patients with RA and CCP and with RA and without CCP, patients with other rheumatic diseases (Psoriatic Rheumatism, Primary Sjögren Syndrome, Ankylosis Spondylitis) and healthy controls
  • Microarray which includes this protein complex and a
  • WO 2009/030226 discloses marker sequences for rheumatoid arthritis and their diagnostic use together with a
  • Marker sequences for rheumatoid arthritis in particular a protein biochip and its use.
  • Marker sequences for diagnosis of RA methods for diagnosing RA using these marker sequences, methods for stratifying, an array of marker sequences, an assay / protein biochip, the use of the assembly, Diagnostics comprising the marker sequences, a target for treatment and therapy, and the use of the marker sequences to perform apheresis.
  • the RA-specific expression clones were obtained in DE 10 2007 041 656 AI in that 10 or more patient samples were individually screened against a cDNA expression library and identified by comparison with 10 or more healthy samples.
  • Fig. 1 the differential
  • the object of the present invention is therefore the
  • the invention provides a method for identifying marker sequences for rheumatoid arthritis (RA), comprising the steps of: a) selecting marker sequence candidates by screening protein biochips representing a cDNA expression library with at least 10 patient samples and at least 10 samples of healthy subjects and wherein each sample is measured individually and
  • Partial proteins are coupled, d) validation of the coupled to the beads
  • Marker sequence candidates by means of samples of patients with RA and samples of healthy persons by using marker sequences for RA with the samples of
  • marker sequences to be examined or the sequences binding to these marker sequences are immobilized on a solid, planar support.
  • beads which therefore differ, among other things, in terms of their sensitivity and specificity of conventional microarrays.
  • bead arrays are either impregnated with beads at different concentrations
  • Fluorescent dye or e.g. created by barcode technology.
  • the beads are addressable and can be used to detect specific binding events occurring on their own
  • Bead technology is based on microscopically small spherical beads or platelets called microspheres or beads. These beads can be used analogously to ELISA and Western Blot as
  • Solid phase for biochemical detection reactions serve.
  • bead types which differ for example in their fluorescent color and each of which carries its own specific detection reagent on the surface. In this way, a corresponding number of different detection reactions can be carried out simultaneously in a very small sample volume.
  • bead arrays specific interactions of two defined biochemical compounds are detectable.
  • the bead-based validation is characterized by a
  • marker sequences with particular specificity can be obtained. For example, marker sequences with which subgroups of patients can be diagnosed within the indication RA.
  • steps c) and d) are carried out in the presence of CPP (cytochrome c peroxidase)
  • Marker sequences are more sensitive to the diagnosis of rheumatoid arthritis than CCP. Using the marker sequences validated in the presence of CCP, a subgroup of RA patients can be diagnosed. In carrying out the
  • the invention relates to a method for identifying marker sequences for rheumatoid arthritis (RA) comprising the steps of: a) selecting marker sequence candidates by screening protein biochips representing a cDNA expression library with at least 10 patient samples and at least 10 samples from healthy subjects, and each sample being measured individually and Marker sequence candidates for RA by a
  • Partial proteins are coupled and wherein the beads also CCP (cytochrome c peroxidase)
  • Marker sequence candidates from c) by means of samples from patients with RA and samples from healthy persons by using marker sequences for RA with the samples from
  • Patients with RA show an interaction and show a lesser or no interaction with the samples of healthy persons and the marker sequences SEQ ID No. 29 to 79, SEQ ID No. 120 to 170, SEQ ID No. 211 to 261, SEQ ID No. 274, SEQ ID NO. 276, SEQ ID No. 278, SEQ ID No. 285 to 288, SEQ ID No. 291, SEQ ID No. 294, SEQ ID No. 296, SEQ ID NO. 298, SEQ ID No. 305 to 308, SEQ ID No. 311, SEQ ID no. 314, SEQ ID No. 316, SEQ ID No. 318, SEQ ID no. 325 to 328, SEQ ID No. 331 are obtained.
  • An embodiment of the method according to the invention is characterized in that an interaction between marker sequence candidate and the samples in step d) is detected by means of a fluorescence signal and wherein the intensity of the fluorescence signal with the strength of the
  • the invention also relates to a marker sequence for
  • Rheumatoid arthritis obtainable by a method according to the invention and wherein the marker sequence is selected from the group of the sequences SEQ ID No. 1 to 182 and SEQ ID. No. 274 to 313, one of the sequences SEQ ID No. 1 to 182 and SEQ ID No. 274 to 313 homologous sequence or a partial sequence of SEQ ID No. 1 to 182 and SEQ ID. No. 274 to 313 or a SEQ ID No. 1 to 182 or SEQ ID. No. 274 to 313 encoded protein or by a partial sequence of SEQ ID NO. 1 to 182 or SEQ ID. No. 274 to 313 encoded protein or by a homologous sequence of SEQ ID NO. 1 to 182 or SEQ ID. No. 274 to 313 encoded protein and a genomic sequences having one of the sequences SEQ ID NO. 1 to 182 or SEQ ID. No. 274 to 313.
  • the invention also relates to a marker sequence for
  • Marker sequence is selected from the group of the sequences SEQ ID NO. 29 to 79, SEQ ID No. 274, SEQ ID No. 276, SEQ ID No. 278, SEQ ID No. 285 to 288, SEQ ID No. 291 and SEQ ID. No. 120 to 170, SEQ ID No. 294, SEQ ID No. 296, SEQ ID No. 298, SEQ ID no. 305 to 308, SEQ ID No. 311, one of the sequences SEQ ID no. 29 to 79, SEQ ID No. 274, SEQ ID No. 276, SEQ ID NO. 278, SEQ ID No. 285 to 288, SEQ ID No. 291 or SEQ ID NO. 120 to 170, SEQ ID No. 294, SEQ ID No.
  • SEQ ID No. 120 to 170 SEQ ID No. 294, SEQ ID NO. 296, SEQ ID No. 298, SEQ ID No. 305 to 308, SEQ ID No. 311 encoded protein or by a partial sequence of SEQ ID NO. 29 to 79, SEQ ID No. 274, SEQ ID No. 276, SEQ ID NO. 278, SEQ ID No. 285 to 288, SEQ ID No. 291 or SEQ ID. No. 120 to 170, SEQ ID No. 294, SEQ ID No. 296, SEQ ID No. 298, SEQ ID No. 305 to 308, SEQ ID No. 311 encoded protein or by a homologous sequence of SEQ ID No. 29 to
  • SEQ ID No. 311 encoded protein or a genomic sequences, one of the sequences SEQ ID No. 29 to 79, SEQ ID NO. 274, SEQ ID No. 276, SEQ ID No. 278, SEQ ID No. 285 to 288, SEQ ID No. 291 or SEQ ID. No. 120 to 170, SEQ ID NO. 294, SEQ ID No. 296, SEQ ID No. 298, SEQ ID No. 305 to 308, SEQ ID No. 311 encoded protein or a genomic sequences, one of the sequences SEQ ID No. 29 to 79, SEQ ID NO. 274, SEQ ID No. 276, SEQ ID No. 278, SEQ ID No. 285 to 288, SEQ ID No. 291 or SEQ ID. No. 120 to 170, SEQ ID No. 294, SEQ ID No. 296, SEQ ID No. 298, SEQ ID No. 305 to 308, SEQ ID NO. 311 includes.
  • the invention also relates to a marker sequences for
  • Rheumatoid arthritis obtainable by a method according to the invention and wherein the marker sequence is selected from the group of the sequences SEQ ID No. 183 to 273, SEQ ID No. 314 to 333, in particular SEQ ID No. 211 to 261, SEQ ID No. 314, SEQ ID no. 316, SEQ ID No. 318, SEQ ID No. 325 to 328, SEQ ID NO. 331st
  • the invention also provides the use of one or more marker sequence (s) according to the invention for the diagnosis of rheumatoid arthritis.
  • One embodiment relates to the use according to the invention, wherein the marker sequence (s) on or from one to
  • One embodiment relates to the use according to the invention, characterized in that 2 or 3, preferably 4 or 5, more preferably 6, 7 or 8 or more different
  • Marker sequences for example 10 to 20 or 30 or more different marker sequences on or from one to
  • One embodiment relates to the use according to the invention, characterized in that the marker sequence (s) is / are applied to a solid support, the solid support being selected from filters, membranes, wafers, for example silicon wafers, glass, metal, plastic, chips,
  • mass spectrometric targets for example magnetic, coated or labeled beads, such as
  • Fluorophore-labeled beads or Luminex beads Fluorophore-labeled beads or Luminex beads.
  • the invention also provides a method for the diagnosis of rheumatoid arthritis, wherein a.) At least one marker sequence according to the invention is applied to a solid support, preferably to a bead and b.) Is brought into contact with body fluid or tissue extract of a patient and
  • the detection of such an interaction can, for example, by a probe, in particular by an antibody
  • the invention also provides a method for
  • Marker sequence is used to examine a sample of the patient.
  • One embodiment relates to a method according to the invention for the diagnosis of rheumatoid arthritis, wherein the
  • the invention also provides an arrangement comprising or consisting of one or more inventive
  • the invention also provides an assay or protein array comprising an arrangement according to the invention.
  • the invention also provides the use of an inventive arrangement or an assay or protein array according to the invention for the identification and / or
  • Characterization of a substance for rheumatoid arthritis containing means for detecting a binding success characterized in that an arrangement or an assay or Protein array with a.
  • Substance is brought into contact and b.) A binding success is detected.
  • the invention also provides a diagnostic agent for
  • Diagnosis of rheumatoid arthritis containing at least one marker sequence according to the invention and optionally further excipients and additives.
  • the invention also provides a target for the treatment or therapy of rheumatoid arthritis, wherein the target is selected from the marker sequences according to the invention.
  • the invention also provides the use of one or more marker sequence (s) according to the invention as
  • an arrangement comprising one or more marker sequences according to the invention is preferably used as affinity material for carrying out the apheresis or blood washing, wherein substances from body fluids of a patient with
  • Rheumatoid arthritis such as blood or plasma
  • Corresponding devices are known in the art, e.g. chromatographic devices containing beads, spheres or chromatographic material, e.g. in a column having the marker sequences of the invention and therefore e.g. (Auto) can selectively withdraw antibodies.
  • the invention also provides the use of at least one marker sequence according to the invention for identifying a subgroup of patients within the group of
  • Marker sequences for the diagnosis of rheumatoid arthritis wherein at least one marker sequence selected from the group of marker sequences SEQ ID No. 1 to 91 or SEQ ID No. 274 to 293 and / or SEQ ID No. 92 to 182 or SEQ ID No. 294 to 313 and / or the genomic sequences that one of the
  • Marker sequence (s) can be identified by a method according to the invention.
  • Method comprises the steps of a) identification of marker sequence candidates by
  • Partial proteins are coupled to the amino acids
  • Biomarkers for Rheumatoid Arthritis for example CCP
  • Biomarker for rheumatoid arthritis such as CCP is performed.
  • a preferred embodiment of the invention relates to the use of marker sequences according to the invention for the diagnosis of rheumatoid arthritis in patients who are CCP-negative, wherein at least one marker sequence selected from the group of marker sequences SEQ ID No. 29 to 79 and / or SEQ ID No. 120 to 170 and / or the genomic sequences which have one of the sequences SEQ ID No. 29 to 79 or 120 to 170 and / or one by the sequences SEQ ID No. 29 to 79 or 120 to 170 coded protein or a partial sequence or a homologue of the sequences SEQ ID No. 29 to 79 or SEQ ID No. 120 to 170 or a protein encoded by the partial sequence or the homologous sequence to or from a to be examined
  • the marker sequences validated in the presence of CCP are more sensitive to the diagnosis of rheumatoid
  • Another particular embodiment of the invention relates to the use of marker sequences according to the invention for the diagnosis of rheumatoid arthritis at an early stage of RA, wherein RA can not yet be detected by means of CCP at this early stage and at least one
  • Marker sequence selected from the group of marker sequences SEQ ID no. 29 to 79 and / or SEQ ID No. 120 to 170 and / or the genomic sequences which have one of the sequences SEQ ID No. 29 to 79 or 120 to 170 and / or one by the sequences SEQ ID No. 29 to 79 or 120 to 170 encoded protein or a partial sequence or a homologue of the sequences SEQ ID NO. 29 to 79 or SEQ ID No. 120 to 170 or a protein encoded by the partial sequence or the homologous sequence to or from a patient to be examined
  • marker sequence (s) for the diagnosis of rheumatoid arthritis, characterized in that the determination is carried out by means of in-vitro diagnosis.
  • Diagnostics for the diagnosis of rheumatoid arthritis containing at least one marker sequence selected from the group of marker sequences SEQ ID No. 1 to 91 or SEQ ID No. 274 to 293 and / or SEQ ID No. 92 to 182 or SEQ ID No. 294 to 313 and / or the genomic sequences that one of the marker sequences.
  • Marker sequence candidates for RA by comparing the results of the screens selected with the RA patient samples and the results of the screens obtained with the samples from healthy subjects, b) preparing the proteins encoded by the marker sequence candidates and / or or partial proteins (peptides) by expression of the cDNA of the marker sequence candidates, c) production of beads on the one or more of the proteins produced in step b) and / or
  • Partial proteins (peptides) and optionally CCP are coupled, d) validation of the coupled to the beads
  • Marker sequence candidates by means of samples of patients with RA and samples of healthy persons by using marker sequences for RA with the samples of
  • Patients with RA show an interaction and show a lesser or no interaction with the samples of healthy individuals and where the marker sequences SEQ ID No. 1 to 182, SEQ ID. No. 183 to 273, SEQ ID No. 274 to 313 and SEQ ID No. 314 to SEQ ID No. 333, or in the presence of CCP, the marker sequences SEQ ID No. 29 to 79, SEQ ID NO. 120 to 170, SEQ ID No. 211 to 261, SEQ ID No.
  • the marker sequences according to the invention were then expressed and validated after coupling of the expressed marker sequence candidates to Luminex beads with the aid of the Luminex beads, z. comparative against known biomarkers for rheumatoid arthritis and as described in the embodiments. As a result, highly specific marker sequences for rheumatoid arthritis could be identified.
  • Beads (beads, globules, originally also called latex particles) denote so-called microspheres or
  • Microparticles used as carriers for biomolecules in tests and assays are required, which are produced by special chemical processes. These methods are known to the person skilled in the art. Beads for different applications are also commercially available (for example from Progen Biotechnik GmbH). Beads can be made of different materials
  • Beads can be labeled with different dyes or dye mixtures and provided with coatings.
  • Biomolecules can be coupled to their surface. For this purpose, different coupling methods are available, which are known to the person skilled in the art, for example adsorption or
  • the surface of the beads may be modified such that directional coupling of the biomolecules on the bead surface, e.g. in connection with spacers, tags or special modifications is possible and whereby the
  • rheumatoid arthritis is for example after
  • At least 2 to 5 or 10, preferably 30 to 50, marker sequences or 50 to 100 or more marker sequences are added to or from one
  • the marker sequences according to the invention can also be combined, supplemented, fused or extended with known biomarkers for this indication.
  • the determination of the marker sequences takes place outside the human body and the determination takes place in an ex vivo / in vitro diagnosis.
  • the invention also has the object of providing a diagnostic device or an assay, in particular a protein biochip, which is useful for the rheumatoid
  • Diagnosis in the sense of this invention means the positive detection of rheumatoid arthritis by means of
  • Marker sequences of the invention and the assignment of patients to the indication rheumatoid arthritis.
  • diagnosis includes medical diagnostics and
  • diagnosis also includes the
  • the invention relates to a method for
  • At least one Marker sequence according to the invention is determined on a patient to be examined. Also included is the
  • therapy control also includes the classification of patients into responders and non-responders with regard to a therapy or its course of therapy.
  • the term "stratification" includes in particular the
  • patient is understood to mean any subject - human or mammal - with the proviso that the subject is being examined for rheumatoid arthritis.
  • marker sequences in the sense of this invention means that the nucleic acid sequence, for example the mRNA, cDNA or the respectively obtainable polypeptide or Protein are significant for rheumatoid arthritis.
  • the mRNA or cDNA or the particular polypeptide or protein obtainable therefrom may interact with substances from the body fluid or tissue extract of a rheumatoid arthritis patient (e.g., antigen (epitope) / antibody (paratope) interaction).
  • substances from the body fluid or tissue extract of a rheumatoid arthritis patient e.g., antigen (epitope) / antibody (paratope) interaction.
  • Marker sequence selected from the group of marker sequences SEQ ID o. 1 to 182 or SEQ ID No. 274 to 313, the
  • An interaction between the body fluid or the tissue extract of a patient and the marker sequences according to the invention is detected, for example a binding, in particular a binding substance to at least one of the marker sequences according to the invention or, in the case of a cDNA, hybridization with a suitable substance under selected conditions, in particular stringent conditions (eg as defined in J. Sambrook, EF Fritsch, T. Maniatis
  • Hybridization conditions is hybridization in 4 x SSC at 37 ° C followed by several washing steps in 1 x SSC
  • Body fluid in particular blood, whole blood, blood plasma, blood serum, patient serum, urine, cerebrospinal fluid, synovial fluid or a tissue extract of the patient.
  • the marker sequences according to the invention can be present in a significantly higher or lower expression rate or concentration in the test subject compared to
  • Marker sequence in a healthy or a subject without RA is an indication of rheumatoid arthritis and the diagnosis of RA.
  • Marker sequences according to the invention can be determined, for example, by means of proteomics or nucleic acid blots.
  • the protein is preferred for a protein
  • the marker sequences according to the invention recognize autoantibodies which are responsible for RA are specific or that are formed in the formation and progression of RA disease and / or are formed increased or decreased. Two or more marker sequences according to the invention can be used to detect autoantibody profiles or changes in
  • SEQ ID o. 1 to 91 and 274 to 293 are the subject of Table 7 and can be clearly identified by the respective cited database entry (also by means of the Internet: http://www.ncbi.nlm.nih.gov/) ( see RefSeq Accession or Gl Accession).
  • the invention also relates to the full-length sequences of the marker sequences according to the invention and the marker sequences as defined in the tables on the known database entries as well as those in the attached sequence listing
  • Protein sequences SEQ ID No. 183 to 273 and SEQ ID No. 314 to 333 in particular the nucleic acid sequences SEQ ID No. 29 to 79 and SEQ ID No. 120 to 170, SEQ ID No. 274, SEQ ID No. 276, SEQ ID NO. 278, SEQ ID No. 285 to 288, SEQ ID No. 291, SEQ ID NO. 294, SEQ ID No. 296, SEQ ID No. 298, SEQ ID No. 305 to 308, SEQ ID NO. 311, and the protein sequences SEQ ID No. 211 to 261, SEQ ID No. 314, SEQ ID No. 316, SEQ ID No. 318, SEQ ID no. 325 to 328, SEQ ID No.
  • the clone sequences according to the invention SEQ ID no. 1 to 91 and SEQ ID No. 274 to 293 are partial sequences, at least with high homology, the marker sequences according to the invention SEQ ID No. 92 to 182 and SEQ ID No. 294 to 313 dar. Particularly preferred are the marker sequences SEQ ID NO. 29 to 79, SEQ ID No. 274, SEQ ID No. 276, SEQ ID No. 278, SEQ ID NO. 285 to 288, SEQ ID No. 291 and the proteins encoded by these marker sequences.
  • marker sequences having P values less than or equal to 0.006, preferably less than or equal to 0.001 or less than or equal to 0.0001, more preferably less than or equal to 0.00001 (see FIG 1, Tables 8 and 8a).
  • the marker sequences SEQ ID No. SEQ ID no. 4 to 15, partial sequences and homologues of SEQ ID no. 4 to 15, as well as the coded thereby peptides / proteins preferred because these marker sequences have
  • homologs of the marker sequences according to the invention are included.
  • homologues homologues
  • Homologues can be protein or
  • Nucleic acid sequences are those sequences which are 50 to 100 nucleotides or amino acids, preferably 70-120 nucleotides or
  • Amino acids particularly preferably 100 to 200 nucleotides or amino acids of one of the marker sequences SEQ ID no. 1 to 333.
  • the marker sequences also include such
  • nucleotide sequence for example the cDNA sequence and the corresponding amino acid sequence, such as
  • Marker sequence may be represented in different amounts in one or more areas on a solid support, for example a bead. This allows a variation of the sensitivity.
  • the regions may each comprise a total of marker sequences, i. a sufficient number
  • marker sequences in particular 2 to 5 or 10 or more marker sequences and, if appropriate, further nucleic acids and / or proteins, in particular biomarkers. However, at least 96 to 25,000 (numerically) or more of different or identical marker sequences and more are preferred
  • Nucleic acids and / or proteins in particular biomarkers. Further preferred are more than 2,500, particularly preferred
  • Another object of the invention relates to an array of marker sequences containing at least one marker sequence a cDNA selected from the group SEQ ID No. 92 to 182 and 294 to 313 or each protein encoded thereby.
  • the array contains at least 2 to 5 or 10, preferably 30 to 50 marker sequences or 50 to 100 or more marker sequences.
  • array means synonymously “array” and insofar as this "array” is used to identify substances to be bound to marker sequences, this is to be understood as an “assay” or a diagnostic device.
  • array means synonymously “array” and insofar as this "array” is used to identify substances to be bound to marker sequences, this is to be understood as an “assay” or a diagnostic device.
  • marker sequences in the form of a grid on a solid support. Furthermore, such arrangements are preferred which allow a high density array of marker sequences and spotting the marker sequences. Such high density spotted assemblies are
  • the term "assay" or diagnostic device also includes such embodiments of a device, such as ELISA (e.g., individual wells
  • Examples are diagnostic ELISA kits from the company Phadia or multiplex ELISA kits
  • Marker sequences according to the invention or combinations of marker sequences are robot-supported on membranes
  • Example "Euroline” from Euroimmun AG Western blot
  • example “Euroline-WB” from Euroimmun AG immunochromatographic methods (for example lateral flow immunoassays, marker sequences or combinations of marker sequences are applied to test strips (Membranen, US Pat
  • Marker sequences are present and available in different quantities based on a spot. Furthermore, the
  • Marker sequences on the solid support e.g., by serial dilution series of e.g.
  • the invention relates to an assay or protein biochip or bead (s) (bead-based assay) from an arrangement containing inventive
  • the marker sequences are present as clones.
  • Such clones can be obtained, for example, by means of a cDNA expression library according to the invention (Büssow et al., 1998 (supra)).
  • such expression libraries become
  • These expression vectors preferably contain inducible promoters. The induction of
  • Expression can e.g. by means of an inductor, such as IPTG.
  • IPTG inductor
  • Suitable expression vectors are described in Terpe et al. (Terpe T Appl Microbiol Biotechnol 2003 Jan; 60 (5): 523-33).
  • Expression libraries are known to the person skilled in the art, these can be prepared according to standard works, such as Sambrook et al., Molecular Cloning, Laboratory Laboratory, 2nd edition (1989), CSH press, Cold Spring Harbor, New York Further preferred are such expression libraries
  • tissue specific e.g., human tissue, especially human organs.
  • expression libraries are also included according to the invention, which can be obtained by exon trapping. Instead of expression library can be spoken synonymously from an expression bank.
  • protein biochips or beads or corresponding expression libraries which have no redundancy (so-called: Uniclone® library) and according to the teachings of WO 99/57311 and WO 99/57312, for example
  • the clones may not be such as transformed bacteria, recombinant phage or transformed cells of mammals, insects, fungi, yeasts or plants.
  • the clones are fixed on a solid support, spotted or immobilized. Therefore, the invention relates to an arrangement, wherein the
  • Marker sequences are present as clones.
  • marker sequences may be in the form of a fusion protein in the particular form
  • the tag may be one such as c-myc, His tag, Arg tag, FLAG, alkaline phosphatase, V5 tag, T7 tag or strep tag, HAT tag, NusA, S-tag, SBP tag , Thioredoxin, DsbA, a fusion protein, preferably a cellulose-binding one
  • Protein Protein, calmodulin-binding protein, glutathione S-transferase or lacZ.
  • a marker sequence can also be made up of several individual ones
  • marker sequences This may involve cloning individual fragments into a large common fragment and expressing this combined fragment.
  • solid support includes embodiments such as a filter, a membrane, a magnetic or fluorophore-labeled bead
  • Silicon wafer, glass, metal, plastic, a chip, a Mass spectrometric target or a matrix Silicon wafer, glass, metal, plastic, a chip, a Mass spectrometric target or a matrix.
  • a filter and beads are preferred according to the invention.
  • the filter is PVDF, nitrocellulose or nylon (e.g., Immobilon P Millipore, Protran Whatman, Hybond N + Amersham).
  • this corresponds to a grid having the order of a microtiter plate (8-12 wells strips, 96 wells, 384 wells or more), a silicon wafer, a chip, a mass spectrometric target or a matrix.
  • beads are used as beads.
  • bead-based multiplex assays are used.
  • the analysis and evaluation of the bead-based assays can be carried out, for example, with a Luminex analysis system, which is carried out on the method of flow cytometry using two different lasers.
  • CVs coefficients of variation
  • Luminex ie bead-based protein arrays
  • Luminex ie bead-based protein arrays
  • several devices can be additionally saved, i. E. Protein printer, hybridizer and array reader, and be replaced by a device.
  • the UNIarray concept is not bound to Luminex, but can also be used on other platforms such as Luminex. Randox, VBC Genomics etc are used.
  • the high measurement accuracy and the low VKs of the individual measurements allow the use of better and new statistical
  • the invention relates to an assay or protein biochip for identifying and
  • Characterizing a substance for rheumatoid arthritis characterized in that an arrangement or assay according to the invention is brought into contact with a.) At least one substance to be investigated, and b.) A binding success
  • the substance to be tested may be any native or non-native biomolecule
  • the binding success is carried out, for example, using commercially available image analysis software (GenePix Pro (Axon Laboratories), Aida (Raytest), ScanArray (Packard Bioscience).
  • protein to marker sequence e.g., protein to marker sequence
  • Antigen / antibody or corresponding "means for detecting the binding success" can, for example, by means of
  • reporter enzymes such as alkaline
  • a readout is e.g. by means of a microarray laser scanner, a CCD camera or visually.
  • the invention relates to a drug / drug or prodrug for rheumatoid
  • the invention also relates to the use of a device according to the invention or an assay for the screening of drugs for rheumatoid arthritis.
  • Figure 2 Volcano plot rheumatoid arthritis vs. control
  • Figure 3 Volcano plot CCP negative in the RA group vs.
  • Protein biochips each performed from a cDNA expression library of a patient and a healthy subject and the differential clones are detected by fluorescence labeling and bioinformatorisch evaluated.
  • Aquaporin 4 for Neuromyolitis Optica various cytokines, typical autoimmune markers etc. produced and measured together with the 3,500 proteins. The inclusion of known
  • Example 2 Selection of Patients and Subjects for the Validation of the marker sequence candidates.
  • RA rheumatoid arthritis
  • control subjects without rheumatoid arthritis
  • Group N N Mean Median SD Min. Max .
  • Table 7 summarizes the clone sequences SEQ ID No. 1 to 91 and 274 to 293 which are specific for rheumatoid arthritis and which are used to identify the sequences specific for rheumatoid arthritis SEQ ID No. 92 to 273 and 294 to 333 were used. The details of the sequence data are shown in the attached sequence listing.
  • vs RA 9322 interactor 10 TRIP10 ref NM. _004240 gi 11342676 lipopolysaccharide
  • Control 54522 ankyrin repeat ANKRD16 ref NM. _019046 gi 58331111 vs RA domain 16
  • Control poly (ADP vs. RA ribose) ref NM. , 0010426
  • Control 3303 heat shock HSPA1A ref NM. _005345 gi 194248072 vs RA 70kDa protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un nouveau procédé pour identifier des séquences marqueurs de la polyarthrite rhumatoïde. L'invention concerne de nouvelles séquences marqueurs découvertes à l'aide du procédé et leur utilisation diagnostique. L'invention concerne en outre des dispositifs diagnostiques contenant ces séquences marqueurs de la polyarthrite rhumatoïde, en particulier une biopuce à protéines ou des billes et leur utilisation.
EP13718795.1A 2012-03-27 2013-03-27 Séquences marqueurs de la polyarthrite rhumatoïde Withdrawn EP2831275A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13718795.1A EP2831275A1 (fr) 2012-03-27 2013-03-27 Séquences marqueurs de la polyarthrite rhumatoïde

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12161628.8A EP2644704A1 (fr) 2012-03-27 2012-03-27 Séquences de marqueurs pour l'arthrite rhumatoïde
EP12182857 2012-09-03
PCT/EP2013/056627 WO2013170994A1 (fr) 2012-03-27 2013-03-27 Séquences marqueurs de la polyarthrite rhumatoïde
EP13718795.1A EP2831275A1 (fr) 2012-03-27 2013-03-27 Séquences marqueurs de la polyarthrite rhumatoïde

Publications (1)

Publication Number Publication Date
EP2831275A1 true EP2831275A1 (fr) 2015-02-04

Family

ID=48190467

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13718795.1A Withdrawn EP2831275A1 (fr) 2012-03-27 2013-03-27 Séquences marqueurs de la polyarthrite rhumatoïde

Country Status (3)

Country Link
US (1) US20150293120A1 (fr)
EP (1) EP2831275A1 (fr)
WO (1) WO2013170994A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146174A1 (fr) * 2015-03-17 2016-09-22 Biontech Ag Compositions et méthodes pour le diagnostic et le traitement du cancer
BR112018069783A2 (pt) * 2016-03-30 2019-01-29 Macroarray Diagnostics Gmbh arranjo antigênico compreendendo grupos de grânulos revestidos com antígeno, fixadas em um carreador sólido para detectar uma imunoglobulina específica para um antígeno detector ou para um conjunto de antígenos detectores, método de detecção de uma imunoglobulina específica para um antígeno detector ou para um conjunto de antígenos detectores, um cartucho e um kit compreendendo o arranjo antigênico
EP3258268A1 (fr) * 2016-06-15 2017-12-20 Protagen AG Sequences de marqueurs pour la commande de therapie de patients atteints de polyarthrite rhumatoïde
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
CN112285363A (zh) * 2020-10-16 2021-01-29 中国科学院心理研究所 自身免疫类神经疾病的诊断
WO2024226265A1 (fr) * 2023-04-28 2024-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gènes synthétiques mmab et vecteurs aav pour traiter la carence en cobalamine b

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096317A1 (en) * 2000-10-06 2003-05-22 Smith Terry J. Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders
WO2006020767A2 (fr) * 2004-08-13 2006-02-23 Genentech, Inc. Composes a base de 2-amido-thiazole presentant une activite inhibitrice enzymatique utilisant de l'adenosine triphosphate (atp), et compositions, et leurs utilisations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
ATE283930T1 (de) 1998-04-30 2004-12-15 Max Planck Gesellschaft NEUE METHODE ZUR SELEKTION VON KLONEN EINER EXPRESSIONSBIBLIOTHEK MITTELS ßREARRAYINGß
CA2326390A1 (fr) 1998-04-30 1999-11-11 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nouveau procede permettant l'identification de clones conferant une propriete biologique desiree dans une banque d'expression
US20070254300A1 (en) 1999-12-02 2007-11-01 Myriad Genetics, Incorporated Compositions and methods for treating inflammatory disorders
EP1456418A4 (fr) * 2001-12-20 2006-07-26 Merck & Co Inc Identification de sites polymorphes dans le gene humain mglur8 et utilisations associees
WO2005032328A2 (fr) 2003-05-21 2005-04-14 Millennium Pharmaceuticals, Inc. Compositions, trousses et methodes d'identification, d'evaluation, de prevention et de traitement de la polyarthrite rhumatoide
US20060127963A1 (en) 2003-11-21 2006-06-15 Lebrun Stewart J Microarray-based analysis of rheumatoid arthritis markers
JP2005278479A (ja) 2004-03-29 2005-10-13 Hidetoshi Inoko 関節リウマチ検査用マーカー遺伝子
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
DE102007041656A1 (de) 2007-09-03 2009-05-07 Protagen Ag Markersequenzen für rheumatoide Arthritis und deren Verwendung
CA2698437A1 (fr) 2007-09-03 2009-03-12 Protagen Ag Sequences de marqueurs de la polyarthrite rhumatoide et leur utilisation
EP2286233A2 (fr) 2008-05-14 2011-02-23 INSERM (Institut National de la Santé et de la Recherche Medicale) Procédés et kits pour le diagnostic de la polyarthrite rhumatoïde

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096317A1 (en) * 2000-10-06 2003-05-22 Smith Terry J. Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders
WO2006020767A2 (fr) * 2004-08-13 2006-02-23 Genentech, Inc. Composes a base de 2-amido-thiazole presentant une activite inhibitrice enzymatique utilisant de l'adenosine triphosphate (atp), et compositions, et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2013170994A1 *
TERESINA LARAGIONE ET AL: "invamTOR Regulates the Invasive Properties of Synovial Fibroblasts in Rheumatoid Arthritis Teresina", MOLECULAR MEDICINE, vol. 16, no. 9-10, 27 May 2010 (2010-05-27), WASHINGTON, DC; US, pages 1, XP055329748, ISSN: 1076-1551, DOI: 10.2119/molmed.2010.00049 *

Also Published As

Publication number Publication date
WO2013170994A1 (fr) 2013-11-21
US20150293120A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
EP2971285B1 (fr) Biomarqueurs sanguins prédisant la persistance d'un dysfonctionnement cognitif après commotion
EP2831275A1 (fr) Séquences marqueurs de la polyarthrite rhumatoïde
EP2441848A1 (fr) Séquences de marqueur pour le lupus érythémateux systémique et son utilisation
EP3472620A2 (fr) Séquences de marqueur utilisées pour le suivi thérapeutique de patients présentant une polyarthrite rhumatoïde
EP2884278A2 (fr) Séquences de marqueurs pour l'arthrite rhumatoïde et leur utilisation
US12174187B2 (en) Methods for detecting multiple sclerosis (MS) diagnostic autoantibodies
EP2712934A2 (fr) Séquences de marqueurs pour les maladies avec inflammation de la prostate, carcinome de la prostate et leur utilisation
EP2437060A1 (fr) Séquences de marqueurs pour la sclérose multiple et leur utilisation
DE102007062847A1 (de) Markersequenzen für neurodegenerative Erkrankungen und deren Verwendung
EP3436828A1 (fr) Séquences de marqueurs pour la polyarthrite rhumatoïde
EP2644704A1 (fr) Séquences de marqueurs pour l'arthrite rhumatoïde
EP3147663A2 (fr) Séquences de marqueurs pour la sclérose multiple et leur utilisation
EP2780471A2 (fr) Nouveau procédé d'identification de séquences de marqueurs spécifiques pour le cancer de la prostate
EP2487251A1 (fr) Séquences de marqueur pour le diagnostic d'un carcinome de la prostate et leur utilisation
DE102010042359A1 (de) Markersequenzen für Multiple Sklerose und deren Verwendung
EP2275568A1 (fr) Séquences de marqueurs pour l'adiposité et leur utilisation
HK1144015A (en) Marker sequences for rheumatoid arthritis and use thereof
DE102007041654A1 (de) Markersequenzen für juvenile idiopathische Arthritis und deren Verwendung
HK1143995A (en) Marker sequences for multiple sclerosis and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141027

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
PUAG Search results despatched under rule 164(2) epc together with communication from examining division

Free format text: ORIGINAL CODE: 0009017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170103

B565 Issuance of search results under rule 164(2) epc

Effective date: 20170103

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180703